文献速递淋巴瘤

新型淋巴瘤相关巨噬细胞相互作用特征(LAMIS)在DSHNHL临床试验队列中为弥漫性大B细胞淋巴瘤提供稳健的风险预后分层

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
PubMed 文献 · Leukemia · 2019-09-17

研究构建了基于NanoString的淋巴瘤相关巨噬细胞相互作用特征(LAMIS),适用于FFPE材料,并在德国高级别非霍奇金淋巴瘤研究组(DSHNHL)466例前瞻性临床试验患者中验证。LAMIS高表达患者EFS、PFS和OS较短,多因素分析显示其独立于IPI因素、COO、MYC重排和双表达状态。LAMIS高表达合并双表达状态患者预后极差且早期复发。

要点

  • LAMIS高表达与DLBCL患者更短的EFS、PFS和OS相关。
  • LAMIS预后价值独立于IPI、COO、MYC重排和双表达状态。
  • LAMIS高表达合并双表达状态提示预后极差和早期复发。

核心结论

  • LAMIS高表达是DLBCL独立的不良预后因素,强调微环境在预后中的重要性。
  • 联合微环境特征、IPI和双表达状态可能为靶向治疗提供新依据。

研究设计与样本

  • 研究构建了基于NanoString检测的LAMIS,适用于FFPE材料。
  • 在466例纳入DSHNHL前瞻性临床试验的DLBCL患者中验证其临床影响。

主要发现

  • LAMIS高表达患者EFS、PFS和OS较短。
  • 多因素分析显示LAMIS独立于IPI因素:EFS HR 1.7(95%CI 1.2-2.4,p=0.001),PFS HR 1.8(95%CI 1.2-2.5,p=0.001),OS HR 1.8(95%CI 1.3-2.7,p=0.001)。
  • 调整IPI因素后,LAMIS独立于COO、MYC重排和双表达状态。
  • LAMIS高表达合并双表达状态定义了一个预后极差且早期复发的亚组。

临床怎么用

  • LAMIS可用于FFPE样本的DLBCL风险分层,辅助识别高危患者。
  • 联合LAMIS、IPI和双表达状态可能优化预后评估及靶向治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is a disease with heterogeneous outcome. Stromal signatures have been correlated to survival in DLBCL. Their use, however, is hampered by the lack of assays for formalin-fixed paraffin-embedded material (FFPE). We constructed a lymphoma-associated macrophage interaction signature (LAMIS) interrogating features of the microenvironment using a NanoString assay applicable to FFPE. The clinical impact of the signature could be validated in a cohort of 466 patients enrolled in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Patients with high expression of the signature (LAMIShigh) had shorter EFS, PFS, and OS. Multivariate analyses revealed independence from IPI factors in EFS (HR 1.7, 95% CI 1.2-2.4, p-value = 0.001), PFS (HR 1.8, 95% CI 1.2-2.5, p-value = 0.001) and OS (HR 1.8, 95% CI 1.3-2.7, p-value = 0.001). Multivariate analyses adjusted for the IPI factors showed the signature to be independent from COO, MYC rearrangements and double expresser status (DE). LAMIShigh and simultaneous DE status characterized a patient subgroup with dismal prognosis and early relapse. Our data underline the importance of the microenvironment in prognosis. Combined analysis of stromal features, the IPI and DE may provide a new rationale for targeted therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Staiger AM, Altenbuchinger M, Ziepert M, et al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2019. PMID: 31530861. doi:10.1038/s41375-019-0573-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。